Investor Relations

Diagonal Bio is a Swedish biotech company that has developed a ground breaking universal technology platform for the quick and accurate detection of genetic markers in genetic material (DNA and RNA).

Background

Diagonal Bio AB is a Swedish medical technology company founded in 2020 with the vision of limiting the spread of infectious diseases by creating a user-friendly, cost-effective diagnostic platform with high accuracy. Based on its patented technology, Diagonal Bio plans to develops a diagnostic systems, PANVIRAL™, that have the potential to fulfill the vision and thereby facilitate the challenge of rapidly and accurately identifying genetic markers for infectious diseases.

Diagonal Bio’s patented technology can also be used for other purposes outside the market segment for in-vitro diagnostics, for example as a general laboratory equipment quick, accurate and cost-effective identification of genetic markers (LAMPlify®).

Diagonal Bio’s patented technology

Diagonal Bio’s patented technology offers the same accuracy as today’s leading diagnostic method, PCR, but is not dependent on complicated logistics or large central laboratories and is therefore significantly faster and more cost-effective. With the help of the Company’s technology, today’s and future infectious diseases can be diagnosed within 10–15 minutes of sampling, in connection with a visit to, for example, a primary care unit.

Diagonal Bio’s platform technology can also be used for other purposes outside the market segment for in-vitro diagnostics, for example as a general laboratory equipment quick, accurate and cost-effective identification of genetic markers (LAMPlify®). This, too, with the same high accuracy as today’s PCR-based techniques, but in a significantly faster, simpler and more cost-effective.

[1] Agricultural and Environmental Diagnostics Market Size (2028) (businessresearchinsights.com)

[2] Food Safety Testing Market Size Will Attain 35.6 Billion by (globenewswire.com)

[3] Infectious Disease Diagnostic Market Statistics | Forecast – 2030 (alliedmarketresearch.com)

Press Releases

Subscribe

Diagonal Bio announces change of news plattform

Non-regulatory

Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) announces that, effective Monday, 28 April 2025, the Company will transition its news distribution service from Cision News to Modular Finance (MFN).

Read more

Diagonal Bio granted patent in Japan

Non-regulatory

Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) announces that the Japanese Patent Office has confirmed the grant of a patent (application number: EP3987059B1) to Diagonal Bio for the Company’s key technology (‘A DNA/RNA detection platform’).

Read more

Nomination Committee change in Diagonal Bio AB (publ.)

Non-regulatory

Diagonal Bio announces a change the Nomination Committee for the Annual General Meeting (AGM) on May 20, 2025.

Read more

Trading in Diagonal Bio’s shares and warrants of series TO 2 on NGM Nordic SME begins today

Non-regulatory

Today, 19 March 2025, is the first day of trading in Diagonal Bio AB’s (publ) (“Diagonal Bio” or “the Company”) securities on NGM Nordic SME (“NGM”). The shares are traded with ISIN code SE0015961826 under the ticker DIABIO, the warrants of series TO 2 are traded with ISIN code SE0023615968 under the ticker DIABIO TO2. The shareholders do not need to take any action in connection with the change of marketplace.

Read more

Diagonal Bio’s CEO Karin Wehlin increases ownership

Non-regulatory

Diagonal Bio AB’s (”Diagonal Bio” or the ”Company”) CEO, Karin Wehlin, has directly and through Wehlin’s fully owned company WW Advise AB purchased 8,500,000 shares in the Company to a total price of approximately SEK 170,000 (average price SEK 0.02 per share). The acquisition has been made in the market during 11-12 February 2025.  

Read more

News

Revisor

Mazars, Revision

Scheelevägen 17
223 63 Lund
Sweden

Articles of association

Contact us

Karin Wehlin
CEO, Diagonal Bio
Medicon Village, Lund
Phone: +46 (0)70 305 24 88
kw@diagonalbio.com

Certified advisor

Svensk Kapitalmarknadsgranskning AB
www.skmg.se

Phone: +46 (0)8 913 008
E-mail: ca@skmg.se

Issuer

Nordic Issuing AB
Stortorget 3
211 22 Malmö